PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
ZÜRICH, Switzerland, Dec. 08, 2022., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics based on its proprietary antibody-based MHC-targeting
/PRNewswire/ Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced today the.